Misonix (NASDAQ:MSON) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Institutional and Insider Ownership

12.9% of Misonix shares are held by institutional investors. Comparatively, 3.3% of Cesca Therapeutics shares are held by institutional investors. 24.6% of Misonix shares are held by insiders. Comparatively, 15.7% of Cesca Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Misonix and Cesca Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Misonix $36.68 million 4.66 -$7.61 million N/A N/A
Cesca Therapeutics $14.52 million 0.51 -$21.22 million ($0.98) -0.35

Misonix has higher revenue and earnings than Cesca Therapeutics.

Profitability

This table compares Misonix and Cesca Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Misonix -20.75% -7.91% -6.69%
Cesca Therapeutics -322.75% -18.05% -10.84%

Risk and Volatility

Misonix has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of -0.96, meaning that its stock price is 196% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Misonix and Cesca Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Misonix 0 0 2 0 3.00
Cesca Therapeutics 0 0 1 0 3.00

Misonix presently has a consensus target price of $26.00, suggesting a potential upside of 43.65%. Cesca Therapeutics has a consensus target price of $1.50, suggesting a potential upside of 341.18%. Given Cesca Therapeutics’ higher probable upside, analysts clearly believe Cesca Therapeutics is more favorable than Misonix.

Summary

Misonix beats Cesca Therapeutics on 10 of the 11 factors compared between the two stocks.

Misonix Company Profile

Misonix, Inc. is a medical device company, which engages in the design, development, manufacture and marketing of therapeutic ultrasonic medical devices. Its products include the bonescalpel cutting system, which is used for surgical procedures of the spine and on maxillofacial procedures; the sonastar surgical aspirator, which is used to emulsify and remove soft and hard tumors; the sonicone wound cleansing and debridement system, which offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells. The company’s ultrasonic medical devices are used in the following surgeries: spine, neuro, orthopedic, wound debridement, cosmetic, laparoscopic, and medical applications. The company was founded by Howard Alliger in 1959 and is headquartered in Farmingdale, NY.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.